Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arthritis Rheumatol
Autori principali: Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Pediatric Rheumatology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://ncbi.nlm.nih.gov/pubmed/29342499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40418
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi